BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs PSMA ADC (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 19 Jun 2015 Status changed from active, no longer recruiting to completed.
- 24 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.